Navigation Links
SeraCare Life Sciences Announces Renewal of National Institutes of Health Contract to Support Research
Date:5/2/2011

MILFORD, Mass., May 2, 2011 /PRNewswire/ -- SeraCare Life Sciences announced today that the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has awarded a new contract to SeraCare, replacing the current contract which expired on April 30, 2011. Under this contract, SeraCare, at the direction of the NHLBI, will advise on proper collection, processing and storage for biorepository collections. SeraCare will also continue to acquire, store and distribute biospecimens to the scientific community for use in research related to transfusion-transmitted diseases and a variety of other disorders of the blood and the cardiovascular and respiratory systems. The contract is valued at $17.6 million over a five-year term, for an average of $3.5 million per year, if all options are exercised by the NHLBI.

(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO)

"The National Institutes of Health is a long-standing, highly valued customer of SeraCare's services business and its commitment to a continued relationship speaks to SeraCare's exemplary leadership in this space," said Susan Vogt, President and Chief Executive Officer of SeraCare. "SeraCare's biorepository is a best-in-class facility. We store and manage more than 15 million biological samples for government and commercial customers that are critical for scientific research, disease control, drug and diagnostic development and national defense. Our relationship with the National Heart, Lung, and Blood Institute has been in place for more than 12 years and we are pleased to continue this important strategic collaboration."

This project has been funded in whole with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract No.HHSN268201100031C.

About SeraCare Life Sciences, Inc.

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry. www.seracare.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding the maximum amount of potential revenue from the NHLBI contract, the possible exercise of options under the NHLBI contract, SeraCare's obligations under the contract and the expected impact of the NHLBI contract on SeraCare's financial results are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, failure of the NHLBI to exercise options under the contract, the potential for termination of the NHLBI contract at the convenience of the government or for other reasons, the potential for renegotiation of the NHLBI contract over the five-year term of the contract, the potential failure to fulfill obligations under the contract, failure to maintain proper inventory levels, interruption in our supply of products or raw materials, actions of SeraCare's competitors, and changes in the regulatory environment. Many of these factors are beyond our ability to control or predict.

Contacts
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
508-244-6400

Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060


'/>"/>
SOURCE SeraCare Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Caliper Life Sciences Reports First Quarter 2011 Results
2. Particle Sciences and Celanese EVA Performance Polymers Collaborate to Accelerate Drug-Eluting Device Combinations
3. Neurocrine Biosciences to Present at the Deutsche Bank 36th Annual Healthcare Conference
4. Transgenomic, Inc. Presents Its Latest Technology at the BIT Life Sciences World DNA and Genome Day Conference, Dalian, China
5. Advanced Life Sciences Ticker Symbol Reverts Back to ADLS.OB
6. Caliper Life Sciences to Present at the 36th Annual Deutsche Bank Health Care Conference
7. Caliper Life Sciences First Quarter Results Conference Call Notice
8. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
9. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
10. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
11. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ... Company will ring the Nasdaq Closing Bell at the ... at 4:00 p.m. ET on Tuesday, February ... Adrian Adams , will perform the honorary ... 4:00 p.m. ET.  A live webcast will be available ...
(Date:2/12/2016)... Ungarn, February 12, 2016 ... sich auf den ungedeckten medizinischen Bedarf bei ... Ergebnisse seines klinischen Forschungsprogramms bekannt. Das Programm, ... ergab Verbesserungen ihrer respiratorischen Funktionen und anderer ... , ein Medizintechnikunternehmen, das sich auf den ...
(Date:2/11/2016)... , Feb. 11, 2016 Stem cells ... are characterized by self-renewal and the capacity to differentiate ... relatively new discovery, as the first mouse embryonic stem ... was not until 1995 that the first culturing of ... stem cells were not produced until 2006 As a ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... When an Au Pair comes all the way ... they are in for and they are often worried things won’t go well. More often ... for. This year’s Au Pair of the Year winner’s all commented how their Au Pairs ...
(Date:2/12/2016)... ... February 12, 2016 , ... According to an ... beginning to account for a significant portion of hernia repairs throughout the United States. ... Beverly Hills Hernia Center notes that this trend has not only been expected, but ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination ... 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination ... garnering increased attention from all stakeholders in the development of new chemical entities. ...
(Date:2/12/2016)... CULVER CITY, California (PRWEB) , ... February 12, 2016 , ... ... to announce their participation in Red Carpet Events LA GRAMMY’s Style Lounge Event. Coco ... and healthy way to stay hydrated before the big event. The invitation-only gifting suite, ...
Breaking Medicine News(10 mins):